Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge conference assessing opportunities for combination therapy

Thomas J. Lynch, George R. Blumenschein, Jeffrey A. Engelman, Igor Espinoza-Delgado, Ramaswamy Govindan, Jeff Hanke, Nasser H. Hanna, John V. Heymach, Fred R. Hirsch, Pasi A. Janne, Rogerio C. Lilenbaum, Ronald B. Natale, Gregory J. Riely, Lecia V. Sequist, Geoffrey I. Shapiro, Alice Shaw, Frances A. Shepherd, Mark Socinski, A. Gregory Sorensen, Heather A. WakeleeAaron Weitzman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The promise of effective targeted therapy for lung cancer requires rigorous identification of potential targets combined with intensive discovery and development efforts aimed at developing effective "drugs" for these targets. We now recognize that getting the right drug to the right target in the right patient is more complicated than one could have imagined a decade ago. As knowledge of targets and development of agents have proliferated and advanced, so too have data demonstrating the biologic heterogeneity of tumors. The finding that lung cancers are genetically diverse and can exhibit several pathways of resistance in response to targeted agents makes the prospect for curative therapy more daunting. It is becoming increasingly clear that single-agent treatment will be the exception rather than the rule. This information raises important new questions about the development and assessment of novel agents in lung cancer treatment: (1) How do we identify the most important drug targets for tumor initiation and maintenance? (2) What is the best way to assess drug candidates that may only be relevant in a small fraction of patients? (3) What models do we use to predict clinical response and identify effective combinations? And (4) how do we bring combination regimens to the clinic, particularly when the agents are not yet approved individually and may be under development from different companies? The Fifth Cambridge Conference on Novel Agents in the Treatment of Lung Cancer was held in Cambridge, Massachusetts, on October 1-2, 2007, to discuss these questions by reviewing recent progress in the field and advancing recommendations for research and patient care. New information, conclusions, and recommendations considered significant for the field by the program faculty are summarized here and presented at greater length in the individual articles and accompanying discussions that comprise the full conference proceedings. A CME activity based on this summary is also available at www.informedicalcme.com/cme.

Original languageEnglish (US)
Pages (from-to)S107-S112
JournalJournal of Thoracic Oncology
Volume3
Issue number6 6 SUPPL 2
DOIs
StatePublished - Jun 2008

Fingerprint

Lung Neoplasms
Pharmaceutical Preparations
Therapeutics
Patient Rights
Neoplasms
Patient Care
Maintenance
Research

Keywords

  • Biopsies
  • EGFR
  • Lung cancer
  • Novel targets
  • Profiling
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Lynch, T. J., Blumenschein, G. R., Engelman, J. A., Espinoza-Delgado, I., Govindan, R., Hanke, J., ... Weitzman, A. (2008). Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge conference assessing opportunities for combination therapy. Journal of Thoracic Oncology, 3(6 6 SUPPL 2), S107-S112. https://doi.org/10.1097/JTO.0b013e318174e9d3

Summary statement novel agents in the treatment of lung cancer : Fifth Cambridge conference assessing opportunities for combination therapy. / Lynch, Thomas J.; Blumenschein, George R.; Engelman, Jeffrey A.; Espinoza-Delgado, Igor; Govindan, Ramaswamy; Hanke, Jeff; Hanna, Nasser H.; Heymach, John V.; Hirsch, Fred R.; Janne, Pasi A.; Lilenbaum, Rogerio C.; Natale, Ronald B.; Riely, Gregory J.; Sequist, Lecia V.; Shapiro, Geoffrey I.; Shaw, Alice; Shepherd, Frances A.; Socinski, Mark; Sorensen, A. Gregory; Wakelee, Heather A.; Weitzman, Aaron.

In: Journal of Thoracic Oncology, Vol. 3, No. 6 6 SUPPL 2, 06.2008, p. S107-S112.

Research output: Contribution to journalArticle

Lynch, TJ, Blumenschein, GR, Engelman, JA, Espinoza-Delgado, I, Govindan, R, Hanke, J, Hanna, NH, Heymach, JV, Hirsch, FR, Janne, PA, Lilenbaum, RC, Natale, RB, Riely, GJ, Sequist, LV, Shapiro, GI, Shaw, A, Shepherd, FA, Socinski, M, Sorensen, AG, Wakelee, HA & Weitzman, A 2008, 'Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge conference assessing opportunities for combination therapy', Journal of Thoracic Oncology, vol. 3, no. 6 6 SUPPL 2, pp. S107-S112. https://doi.org/10.1097/JTO.0b013e318174e9d3
Lynch, Thomas J. ; Blumenschein, George R. ; Engelman, Jeffrey A. ; Espinoza-Delgado, Igor ; Govindan, Ramaswamy ; Hanke, Jeff ; Hanna, Nasser H. ; Heymach, John V. ; Hirsch, Fred R. ; Janne, Pasi A. ; Lilenbaum, Rogerio C. ; Natale, Ronald B. ; Riely, Gregory J. ; Sequist, Lecia V. ; Shapiro, Geoffrey I. ; Shaw, Alice ; Shepherd, Frances A. ; Socinski, Mark ; Sorensen, A. Gregory ; Wakelee, Heather A. ; Weitzman, Aaron. / Summary statement novel agents in the treatment of lung cancer : Fifth Cambridge conference assessing opportunities for combination therapy. In: Journal of Thoracic Oncology. 2008 ; Vol. 3, No. 6 6 SUPPL 2. pp. S107-S112.
@article{e8a423ca71ec4a9a8a741ed8c26ce136,
title = "Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge conference assessing opportunities for combination therapy",
abstract = "The promise of effective targeted therapy for lung cancer requires rigorous identification of potential targets combined with intensive discovery and development efforts aimed at developing effective {"}drugs{"} for these targets. We now recognize that getting the right drug to the right target in the right patient is more complicated than one could have imagined a decade ago. As knowledge of targets and development of agents have proliferated and advanced, so too have data demonstrating the biologic heterogeneity of tumors. The finding that lung cancers are genetically diverse and can exhibit several pathways of resistance in response to targeted agents makes the prospect for curative therapy more daunting. It is becoming increasingly clear that single-agent treatment will be the exception rather than the rule. This information raises important new questions about the development and assessment of novel agents in lung cancer treatment: (1) How do we identify the most important drug targets for tumor initiation and maintenance? (2) What is the best way to assess drug candidates that may only be relevant in a small fraction of patients? (3) What models do we use to predict clinical response and identify effective combinations? And (4) how do we bring combination regimens to the clinic, particularly when the agents are not yet approved individually and may be under development from different companies? The Fifth Cambridge Conference on Novel Agents in the Treatment of Lung Cancer was held in Cambridge, Massachusetts, on October 1-2, 2007, to discuss these questions by reviewing recent progress in the field and advancing recommendations for research and patient care. New information, conclusions, and recommendations considered significant for the field by the program faculty are summarized here and presented at greater length in the individual articles and accompanying discussions that comprise the full conference proceedings. A CME activity based on this summary is also available at www.informedicalcme.com/cme.",
keywords = "Biopsies, EGFR, Lung cancer, Novel targets, Profiling, VEGF",
author = "Lynch, {Thomas J.} and Blumenschein, {George R.} and Engelman, {Jeffrey A.} and Igor Espinoza-Delgado and Ramaswamy Govindan and Jeff Hanke and Hanna, {Nasser H.} and Heymach, {John V.} and Hirsch, {Fred R.} and Janne, {Pasi A.} and Lilenbaum, {Rogerio C.} and Natale, {Ronald B.} and Riely, {Gregory J.} and Sequist, {Lecia V.} and Shapiro, {Geoffrey I.} and Alice Shaw and Shepherd, {Frances A.} and Mark Socinski and Sorensen, {A. Gregory} and Wakelee, {Heather A.} and Aaron Weitzman",
year = "2008",
month = "6",
doi = "10.1097/JTO.0b013e318174e9d3",
language = "English (US)",
volume = "3",
pages = "S107--S112",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6 6 SUPPL 2",

}

TY - JOUR

T1 - Summary statement novel agents in the treatment of lung cancer

T2 - Fifth Cambridge conference assessing opportunities for combination therapy

AU - Lynch, Thomas J.

AU - Blumenschein, George R.

AU - Engelman, Jeffrey A.

AU - Espinoza-Delgado, Igor

AU - Govindan, Ramaswamy

AU - Hanke, Jeff

AU - Hanna, Nasser H.

AU - Heymach, John V.

AU - Hirsch, Fred R.

AU - Janne, Pasi A.

AU - Lilenbaum, Rogerio C.

AU - Natale, Ronald B.

AU - Riely, Gregory J.

AU - Sequist, Lecia V.

AU - Shapiro, Geoffrey I.

AU - Shaw, Alice

AU - Shepherd, Frances A.

AU - Socinski, Mark

AU - Sorensen, A. Gregory

AU - Wakelee, Heather A.

AU - Weitzman, Aaron

PY - 2008/6

Y1 - 2008/6

N2 - The promise of effective targeted therapy for lung cancer requires rigorous identification of potential targets combined with intensive discovery and development efforts aimed at developing effective "drugs" for these targets. We now recognize that getting the right drug to the right target in the right patient is more complicated than one could have imagined a decade ago. As knowledge of targets and development of agents have proliferated and advanced, so too have data demonstrating the biologic heterogeneity of tumors. The finding that lung cancers are genetically diverse and can exhibit several pathways of resistance in response to targeted agents makes the prospect for curative therapy more daunting. It is becoming increasingly clear that single-agent treatment will be the exception rather than the rule. This information raises important new questions about the development and assessment of novel agents in lung cancer treatment: (1) How do we identify the most important drug targets for tumor initiation and maintenance? (2) What is the best way to assess drug candidates that may only be relevant in a small fraction of patients? (3) What models do we use to predict clinical response and identify effective combinations? And (4) how do we bring combination regimens to the clinic, particularly when the agents are not yet approved individually and may be under development from different companies? The Fifth Cambridge Conference on Novel Agents in the Treatment of Lung Cancer was held in Cambridge, Massachusetts, on October 1-2, 2007, to discuss these questions by reviewing recent progress in the field and advancing recommendations for research and patient care. New information, conclusions, and recommendations considered significant for the field by the program faculty are summarized here and presented at greater length in the individual articles and accompanying discussions that comprise the full conference proceedings. A CME activity based on this summary is also available at www.informedicalcme.com/cme.

AB - The promise of effective targeted therapy for lung cancer requires rigorous identification of potential targets combined with intensive discovery and development efforts aimed at developing effective "drugs" for these targets. We now recognize that getting the right drug to the right target in the right patient is more complicated than one could have imagined a decade ago. As knowledge of targets and development of agents have proliferated and advanced, so too have data demonstrating the biologic heterogeneity of tumors. The finding that lung cancers are genetically diverse and can exhibit several pathways of resistance in response to targeted agents makes the prospect for curative therapy more daunting. It is becoming increasingly clear that single-agent treatment will be the exception rather than the rule. This information raises important new questions about the development and assessment of novel agents in lung cancer treatment: (1) How do we identify the most important drug targets for tumor initiation and maintenance? (2) What is the best way to assess drug candidates that may only be relevant in a small fraction of patients? (3) What models do we use to predict clinical response and identify effective combinations? And (4) how do we bring combination regimens to the clinic, particularly when the agents are not yet approved individually and may be under development from different companies? The Fifth Cambridge Conference on Novel Agents in the Treatment of Lung Cancer was held in Cambridge, Massachusetts, on October 1-2, 2007, to discuss these questions by reviewing recent progress in the field and advancing recommendations for research and patient care. New information, conclusions, and recommendations considered significant for the field by the program faculty are summarized here and presented at greater length in the individual articles and accompanying discussions that comprise the full conference proceedings. A CME activity based on this summary is also available at www.informedicalcme.com/cme.

KW - Biopsies

KW - EGFR

KW - Lung cancer

KW - Novel targets

KW - Profiling

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=44649148421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649148421&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318174e9d3

DO - 10.1097/JTO.0b013e318174e9d3

M3 - Article

C2 - 18520291

AN - SCOPUS:44649148421

VL - 3

SP - S107-S112

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6 6 SUPPL 2

ER -